Novel substituted pyrimidines as HCV replication (replicase) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 2, 2012, Pages 1160-1164

  Kwong, Cecil D ^a   Clark, Jeremy L ^a   Fowler, Anita T ^a   Geng, Feng ^a   Kezar III, Hollis S ^a   Roychowdhury, Abhijit ^a   Reynolds, Robert C ^a   Maddry, Joseph A ^a   Ananthan, Subramaniam ^a   Secrist III, John A ^a   Shih, Neng Yang ^b   Piwinski, John J ^b   Li, Cheng ^b   Feld, Boris ^b   Huang, Hsueh Cheng ^b   Tong, Xiao ^b   George Njoroge, F ^b   Arasappan, Ashok ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 Alkynyl pyrimidine; 5 Azo pyrimidine; Carbanucleoside like; HCV replicase inhibitor; HCV replication inhibitor

Indexed keywords

CARBANUCLEOSIDE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; RAT; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION; VIRUS REPLICATION; WITTIG REACTION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATITIS C; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PYRIMIDINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84855684909     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.091     Document Type: Article

References (15)

1. D. Lavanchy Liver Int. 29 2009 74
2. B.D. Lindenbach, and C.M. Rice Nature 436 2005 933
3. J.J. Feld, and J.H. Hoofnagle Nature 436 2005 967
4. (i) FDA press release dated May 13, 2011, http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm255390.htm.
5. S. Venkatraman, S.L. Bogen, A. Arasappan, F. Bennett, K. Chen, E. Jao, Y.-T. Liu, R. Lovey, S. Hendrata, Y. Huang, W. Pan, T. Parekh, P. Pinto, V. Popov, R. Pike, S. Ruan, B. Santhanam, B. Vibulbhan, W. Wu, W. Yang, J. Kong, X. Liang, J. Wong, R. Liu, N. Butkiewicz, R. Chase, A. Hart, S. Agrawal, P. Ingravallo, J. Pichardo, R. Kong, B. Baroudy, B. Malcolm, Z. Guo, A. Prongay, V. Madison, L. Broske, X. Cui, K.-C. Cheng, T.Y. Hsieh, J.-M. Brisson, D. Prelusky, W. Korfmacher, R. White, S. Bogdanowich-Knipp, A. Pavlovsky, P. Bradley, A.K. Saksena, A. Ganguly, J. Piwinski, V. Girijavallabhan, and F.G. Njoroge J. Med. Chem. 49 2006 6074
6. (i) Telaprevir: FDA press release dated May 23, 2011, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm.
7. R.B. Perni, S.J. Almquist, R.A. Byrn, G. Chandorkar, P.R. Chaturvedi, L.F. Courtney, C.J. Decker, K. Dinehart, C.A. Gates, S.L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y.-P. Luong, B.G. Rao, W.P. Taylor, J.A. Thomson, R.D. Tung, Y. Wei, A.D. Kwong, and C. Lin Antimicrob. Agents Chemother. 50 2006 899
8. R. Flisiak, and A. Parfieniuk Expert Opin. Investig. Drugs 19 1 2010 63
9. A. Birerdinc, and Z.M. Younossi Expert Opin. Emerg. Drugs 15 4 2010 535
10. N.A. Meanwell, J.F. Kadow, and P.M. Scola Annu. Rep. Med. Chem. 44 2009 397
11. V. Lohmann, F. Körner, J.-O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Science 285 1999 110
12. J.B. Rodriguez, and M.J. Comin Mini-Rev. Med. Chem. 3 2003 95
13. S.W. Schneller Curr. Top. Med. Chem. 2 2002 1087
14. C. Torborg, and M. Beller Adv. Synth. Catal. 351 2009 3027
15. R. Rossi, A. Carpita, A. Ribecai, and L. Mannina Tetrahedron 57 2001 2847